How much funding has CircodeBio (环码生物) raised?

CircodeBio (环码生物) has raised $20.0M in total funding, most recently a Series A round.

When was CircodeBio (环码生物) founded?

CircodeBio (环码生物) was founded in 2021.

Where is CircodeBio (环码生物) headquartered?

CircodeBio (环码生物) is headquartered in Shanghai, China.

What industry is CircodeBio (环码生物) in?

CircodeBio (环码生物) operates in Biotech.

How many employees does CircodeBio (环码生物) have?

CircodeBio (环码生物) has 51-200 employees.

CircodeBio (环码生物)

Q: Who are CircodeBio (环码生物)'s investors?

CircodeBio (环码生物)'s investors include Johnson & Johnson Innovation, K2 Venture Capital, Superstring Capital, Kaitai Capital.

环码生物CirCode

Shanghai, China · Founded 2021 · $20.0M raised

Biotech

Headquarters: Shanghai
Employees: 51–200
Founded: 2021
Business Model: B2B

Website: circodebio.com
Total Funding: $20.0M
Last Round: $20.0M Series AAug 2023
Rounds: 2

About

Shanghai CirCode Biomed Co., Ltd (CirCode, 环码生物) is an innovative biotechnology company specializing in the development of circular RNA (circRNA) therapeutics. Unlike linear mRNA, circular RNA is more stable and less immunogenic, giving it advantages across a broader range of therapeutic applications. CirCode has developed proprietary platform technologies for circular RNA drug development and holds multiple patent families covering this novel technology, with pending applications worldwide. The company is committed to advancing scientific and technological achievements to realize the benefits of circular RNA science for patients. CirCode's pipeline targets disease areas where the enhanced stability and reduced immunogenicity of circular RNA provide meaningful advantages over existing nucleic acid therapies.

Summary

CircodeBio (环码生物) is a Biotech company based in Shanghai, China, founded in 2021. It has raised $20.0M in total across 2 rounds, most recently a $20.0M Series A round in Aug 2023. Investors include Johnson & Johnson Innovation, K2 Venture Capital and Superstring Capital.